Study of ODX (OsteoDex) in Multiple Myeloma
A phase 1/2 trial of ODX (Osteodex) in multiple myeloma, run by DexTech Medical AB, now recruiting.
Overview
Study of ODX (OsteoDex) in Multiple Myeloma is a phase 1/2 interventional study registered as NCT06616389 by DexTech Medical AB, with 12 participants planned, started 2023-11-29 and due to reach its primary completion in 2026-01-30. Interventions recorded: ODX (Osteodex).
Setting
A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma
Phase
Phase 1/2
Sponsor
DexTech Medical AB
Registry
Enrolled
12
Similar pages
not linked directly; found by shared links- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialAn Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.